We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+17.67%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$36.9M
Cap. Flow
+$8.73M
Cap. Flow %
1.8%
Top 10 Hldgs %
68.13%
Holding
29
New
1
Increased
3
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
ARTV
Artiva Biotherapeutics
ARTV
+$27.3M
2
EYPT icon
EyePoint Inc
EYPT
+$8.78M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$490K
4
BHVN icon
Biohaven
BHVN
+$350K

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$19.9M
2
QTTB icon
Q32 Bio
QTTB
+$4.52M
3
COGT icon
Cogent Biosciences
COGT
+$2.23M
4
SKYE icon
Skye Bioscience
SKYE
+$1.49M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$37.5K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRDA icon
1
Entrada Therapeutics
TRDA
$282M
$70.4M 14.55%
4,408,379
– –
ELVN icon
2
Enliven Therapeutics
ELVN
$4.15B
$44.8M 9.25%
1,752,174
-858,701
-33% -$19.9M
SKYE icon
3
Skye Bioscience
SKYE
$20.5M
$38.8M 8.01%
9,913,168
-266,337
-3% -$1.49M
ARTV
4
Artiva Biotherapeutics
ARTV
$523M
$36.4M 7.51%
+2,353,304
New +$27.3M
DNTH icon
5
Dianthus Therapeutics
DNTH
$5.8B
$33.7M 6.97%
1,231,619
-1,346
-0.1% -$37.5K
BHVN icon
6
Biohaven
BHVN
$2.01B
$23.9M 4.95%
478,972
+9,000
+2% +$350K
TYRA icon
7
Tyra Biosciences
TYRA
$1.91B
$22.1M 4.56%
939,298
– –
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$20.5M 4.25%
1,285,000
+40,000
+3% +$490K
TECX
9
Tectonic Therapeutic
TECX
$527M
$19.6M 4.05%
646,524
– –
PRAX icon
10
Praxis Precision Medicines
PRAX
$8.52B
$19.6M 4.04%
340,000
– –
CLDX icon
11
Celldex Therapeutics
CLDX
$2.96B
$16.9M 3.49%
497,270
– –
VRDN icon
12
Viridian Therapeutics
VRDN
$2.13B
$16.8M 3.46%
736,595
– –
VKTX icon
13
Viking Therapeutics
VKTX
$3.8B
$15M 3.11%
237,560
– –
PHVS icon
14
Pharvaris
PHVS
$2.25B
$14.8M 3.05%
797,600
– –
ERAS icon
15
Erasca
ERAS
$6.19B
$14.8M 3.05%
5,405,404
– –
MLTX icon
16
MoonLake Immunotherapeutics
MLTX
$1.48B
$14.2M 2.94%
282,313
– –
ANAB icon
17
AnaptysBio
ANAB
$1.59B
$12M 2.48%
357,733
– –
SLN
18
Silence Therapeutics
SLN
$504M
$8.66M 1.79%
476,200
– –
EYPT icon
19
EyePoint Inc
EYPT
$1.04B
$8.39M 1.73%
1,050,000
+1,000,000
+2,000% +$8.78M
COGT icon
20
Cogent Biosciences
COGT
$6.64B
$6.07M 1.25%
561,854
-228,586
-29% -$2.23M
SCPH
21
DELISTED
scPharmaceuticals
SCPH
$5.47M 1.13%
1,200,647
– –
VOR icon
22
Vor Biopharma
VOR
$1.16B
$4.45M 0.92%
318,086
– –
RLYB icon
23
Rallybio
RLYB
$84.6M
$4.25M 0.88%
453,841
– –
GHRS icon
24
GH Research
GHRS
$1.93B
$3.83M 0.79%
572,665
– –
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
$3.8M 0.79%
541,666
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q3 2024 Portfolio in Review

As of Q3 2024, 5AM Venture Management held 29 positions worth $484M, up 8.3% from $447M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

5AM Venture Management's Q3 2024 filing shows 1 new, 3 increased, 4 reduced and 1 closed positions. Its largest new stake was Artiva Biotherapeutics: 2,353,304 shares worth $36.4M. The largest sale was Enliven Therapeutics, an estimated $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q3 2024 buy was Artiva Biotherapeutics: 2,353,304 shares worth $36.4M.
  • 5AM Venture Management added most to EyePoint Inc in Q3 2024, an estimated $8.78M increase.
  • 5AM Venture Management's biggest Q3 2024 reduction was Enliven Therapeutics, cutting an estimated $19.9M.
  • 5AM Venture Management fully exited Q32 Bio in Q3 2024, selling an estimated $4.52M.
  • 5AM Venture Management's ten largest holdings make up 68% of its $484M portfolio in Q3 2024.
  • 5AM Venture Management opened 1 new position and closed 1 in Q3 2024.
  • 5AM Venture Management's portfolio value rose 8.3% quarter-over-quarter to $484M.

Based on 5AM Venture Management's 13F filing for Q3 2024, filed 14 Nov 2024.